A beta imaging with 18F-florbetaben in prodromal Alzheimer's disease: a prospective outcome study
Kevin T Ong, Victor L Villemagne, Alex Bahar-Fuchs, Fiona Lamb, Narelle Langdon, Ana M Catafau, Andrew W Stephens, John Seibyl, Ludger M Dinkelborg, Cornelia B Reininger, Barbara Putz, Beate Rohde, Colin L Masters, Christopher C Rowe
Journal of Neurology Neurosurgery & Psychiatry | BMJ PUBLISHING GROUP | Published : 2015
BACKGROUND: We assessed the clinical utility of β-amyloid (Aβ) imaging with (18)F-florbetaben (FBB) in mild cognitive impairment (MCI) by evaluating its prognostic accuracy for progression to Alzheimer's disease (AD), comparing semiquantitative with visual scan assessment, and exploring the relationships among Aβ, hippocampal volume (HV) and memory over time. METHODS: 45 MCI underwent FBB positron emission tomography, MRI and neuropsychological assessment at baseline and 2 years and clinical follow-up at 4 years. Positive FBB (FBB+), defined by a cortical to cerebellar cortex standardised uptake value ratio (SUVR) ≥ 1.45, was compared with visual assessment by five readers. Amnestic MCI (aMC..View full abstract
Related Projects (2)
Awarded by NHMRC
This study was initiated by Professor CC Rowe, sponsored by Bayer Healthcare AG, Berlin, Germany, and funded in part by NHMRC grant 509166.